Novo Nordisk's CagriSema was associated with significant reduction in blood pressure and showed anti-inflammatory effects while reducing the proportion of patients at risk of developing heart disease over time in new analyses at ObesityWeek®

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Semaglutide 2.4 mg reduced systolic blood pressure by 8.8 mmHg over 68 weeks

  80% confidence

• Overall discontinuation rates due to adverse events were low, with 6% for CagriSema versus 3.7% for placebo

  80% confidence

• Obesity is a chronic relapsing progressive disease process

  80% confidence

• The reduction in hsCRP with CagriSema (68.9%) was greater than with semaglutide 2.4 mg alone (55.4%) or placebo (16.0%)

  80% confidence

• Fewer people on CagriSema were at intermediate-to-high risk of developing atherosclerotic cardiovascular disease within the next 10 years

  80% confidence

• The hsCRP reduction with CagriSema was only partially explained by weight loss, suggesting that the inflammatory effects are not fully weight loss dependent

  80% confidence

• Placebo reduced systolic blood pressure by 2.1 mmHg over 68 weeks

  80% confidence

• CagriSema (2.4 mg/2.4 mg) demonstrated a 10.9 mmHg reduction in systolic blood pressure over 68 weeks

  80% confidence

• The CagriSema data are very encouraging regarding the effects on well-known CV risk factors like high blood pressure

  80% confidence

• 40% of people on blood pressure medications were able to reduce or stop their medication with CagriSema treatment

  80% confidence

• People living with obesity have treatment goals that often include both losing weight and improving overall health

  80% confidence

• Adverse events in REDEFINE 1 were mainly gastrointestinal (79.6% in the CagriSema group versus 39.9% with placebo) and were mostly transient and mild-to-moderate in severity

  80% confidence

• CagriSema treatment demonstrated a nearly 70% reduction in hsCRP, a key inflammatory marker associated with increased cardiovascular risk

  80% confidence

Data points we hold from this source